478841-18-8

Basic information

• Product Name: 2-((4-hydroxycyclohexyl)methyl)isoindoline-1,3-dione
• Synonyms: 2-((4-hydroxycyclohexyl)methyl)isoindoline-1,3-dione
• CAS NO: 478841-18-8
• Molecular Weight: 259.305
• Mol File: 478841-18-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-((4-hydroxycyclohexyl)methyl)isoindoline-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((4-hydroxycyclohexyl)methyl)isoindoline-1,3-dione(478841-18-8)
• EPA Substance Registry System: 2-((4-hydroxycyclohexyl)methyl)isoindoline-1,3-dione(478841-18-8)

Safety Data

• Hazardous Substances Data: 478841-18-8(Hazardous Substances Data)

Upstream product

• 423116-18-1 2-[(4-oxocyclohexyl)methyl]isoindoline-1,3-dione 
• 30482-25-8 (1,4-dioxa-spiro[4.5]dec-8-yl)-methyl-amine 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 189753-93-3 (cis/trans)-4-<(tert-Butyldimethylsilyl)oxy>cyclohexanemethanol 
• 126781-91-7 methyl 4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexanecarboxylate 

Relevant articles and documents

PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.